XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression

Roberta Bartolucci, Jia Wei, Jose Javier Sanchez, Laia Perez-Roca, Imane Chaib, Francesco Puma, Raffaele Farabi, Pedro Mendez, Fausto Roila, Tatsuro Okamoto, Miquel Taron, Rafael Rosell

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Molecular markers can help identify patients with early-stage non-small-cell lung cancer (NSCLC) with a high risk of relapse. Excision repair cross-complementing 1 (ERCC1), Xeroderma pigmentosum group G (XPG), and breast cancer 1 (BRCA1) are involved in DNA damage repair, whereas ribonucleotide reductase M1 (RRM1) is implicated in DNA synthesis. Expression levels of these molecules might therefore have a prognostic role in lung cancer. Patients and Methods: We examined ERCC1, RRM1, XPG, and BRCA1 mRNA levels by real-time quantitative polymerase chain reaction in 54 patients with stage IB-IIB resected NSCLC. A strong correlation was observed between the 4 genes. Results: For patients with low BRCA1, regardless of XPG mRNA expression levels, disease-free survival (DFS) was not reached. For patients with intermediate/high BRCA1 and high XPG, DFS was 50.7 months. However, for patients with intermediate/high BRCA1 and low/intermediate XPG, DFS decreased to 16.3 months (P = .002). Similar differences were observed in overall survival, with median survival not reached for patients with low BRCA1, regardless of XPG levels, or for patients with intermediate/high BRCA1 and high XPG. Conversely, for patients with intermediate/high BRCA1 levels and low/intermediate XPG levels, median sur vival dropped to 25.5 months (P = .007). Conclusion: BRCA1 and XPG were identified as independent prognostic factors for both median survival and DFS. High BRCA1 mRNA expression confers poor prognosis in early NSCLC, and the combination of high BRCA1 and low XPG expression still further increases the risk of shorter survival. These findings can help optimize the customization of adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalClinical Lung Cancer
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Xeroderma Pigmentosum
Non-Small Cell Lung Carcinoma
DNA Repair
Breast Neoplasms
Messenger RNA
Disease-Free Survival
Ribonucleotide Reductases
Survival
Adjuvant Chemotherapy
DNA Damage
Real-Time Polymerase Chain Reaction
Lung Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. / Bartolucci, Roberta; Wei, Jia; Sanchez, Jose Javier; Perez-Roca, Laia; Chaib, Imane; Puma, Francesco; Farabi, Raffaele; Mendez, Pedro; Roila, Fausto; Okamoto, Tatsuro; Taron, Miquel; Rosell, Rafael.

In: Clinical Lung Cancer, Vol. 10, No. 1, 01.2009, p. 47-52.

Research output: Contribution to journalArticle

Bartolucci, R, Wei, J, Sanchez, JJ, Perez-Roca, L, Chaib, I, Puma, F, Farabi, R, Mendez, P, Roila, F, Okamoto, T, Taron, M & Rosell, R 2009, 'XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression', Clinical Lung Cancer, vol. 10, no. 1, pp. 47-52. https://doi.org/10.3816/CLC.2009.n.007
Bartolucci, Roberta ; Wei, Jia ; Sanchez, Jose Javier ; Perez-Roca, Laia ; Chaib, Imane ; Puma, Francesco ; Farabi, Raffaele ; Mendez, Pedro ; Roila, Fausto ; Okamoto, Tatsuro ; Taron, Miquel ; Rosell, Rafael. / XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. In: Clinical Lung Cancer. 2009 ; Vol. 10, No. 1. pp. 47-52.
@article{7b6101ebe5264ac08ab7e731bda5ee5b,
title = "XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression",
abstract = "Background: Molecular markers can help identify patients with early-stage non-small-cell lung cancer (NSCLC) with a high risk of relapse. Excision repair cross-complementing 1 (ERCC1), Xeroderma pigmentosum group G (XPG), and breast cancer 1 (BRCA1) are involved in DNA damage repair, whereas ribonucleotide reductase M1 (RRM1) is implicated in DNA synthesis. Expression levels of these molecules might therefore have a prognostic role in lung cancer. Patients and Methods: We examined ERCC1, RRM1, XPG, and BRCA1 mRNA levels by real-time quantitative polymerase chain reaction in 54 patients with stage IB-IIB resected NSCLC. A strong correlation was observed between the 4 genes. Results: For patients with low BRCA1, regardless of XPG mRNA expression levels, disease-free survival (DFS) was not reached. For patients with intermediate/high BRCA1 and high XPG, DFS was 50.7 months. However, for patients with intermediate/high BRCA1 and low/intermediate XPG, DFS decreased to 16.3 months (P = .002). Similar differences were observed in overall survival, with median survival not reached for patients with low BRCA1, regardless of XPG levels, or for patients with intermediate/high BRCA1 and high XPG. Conversely, for patients with intermediate/high BRCA1 levels and low/intermediate XPG levels, median sur vival dropped to 25.5 months (P = .007). Conclusion: BRCA1 and XPG were identified as independent prognostic factors for both median survival and DFS. High BRCA1 mRNA expression confers poor prognosis in early NSCLC, and the combination of high BRCA1 and low XPG expression still further increases the risk of shorter survival. These findings can help optimize the customization of adjuvant chemotherapy.",
author = "Roberta Bartolucci and Jia Wei and Sanchez, {Jose Javier} and Laia Perez-Roca and Imane Chaib and Francesco Puma and Raffaele Farabi and Pedro Mendez and Fausto Roila and Tatsuro Okamoto and Miquel Taron and Rafael Rosell",
year = "2009",
month = "1",
doi = "10.3816/CLC.2009.n.007",
language = "English",
volume = "10",
pages = "47--52",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression

AU - Bartolucci, Roberta

AU - Wei, Jia

AU - Sanchez, Jose Javier

AU - Perez-Roca, Laia

AU - Chaib, Imane

AU - Puma, Francesco

AU - Farabi, Raffaele

AU - Mendez, Pedro

AU - Roila, Fausto

AU - Okamoto, Tatsuro

AU - Taron, Miquel

AU - Rosell, Rafael

PY - 2009/1

Y1 - 2009/1

N2 - Background: Molecular markers can help identify patients with early-stage non-small-cell lung cancer (NSCLC) with a high risk of relapse. Excision repair cross-complementing 1 (ERCC1), Xeroderma pigmentosum group G (XPG), and breast cancer 1 (BRCA1) are involved in DNA damage repair, whereas ribonucleotide reductase M1 (RRM1) is implicated in DNA synthesis. Expression levels of these molecules might therefore have a prognostic role in lung cancer. Patients and Methods: We examined ERCC1, RRM1, XPG, and BRCA1 mRNA levels by real-time quantitative polymerase chain reaction in 54 patients with stage IB-IIB resected NSCLC. A strong correlation was observed between the 4 genes. Results: For patients with low BRCA1, regardless of XPG mRNA expression levels, disease-free survival (DFS) was not reached. For patients with intermediate/high BRCA1 and high XPG, DFS was 50.7 months. However, for patients with intermediate/high BRCA1 and low/intermediate XPG, DFS decreased to 16.3 months (P = .002). Similar differences were observed in overall survival, with median survival not reached for patients with low BRCA1, regardless of XPG levels, or for patients with intermediate/high BRCA1 and high XPG. Conversely, for patients with intermediate/high BRCA1 levels and low/intermediate XPG levels, median sur vival dropped to 25.5 months (P = .007). Conclusion: BRCA1 and XPG were identified as independent prognostic factors for both median survival and DFS. High BRCA1 mRNA expression confers poor prognosis in early NSCLC, and the combination of high BRCA1 and low XPG expression still further increases the risk of shorter survival. These findings can help optimize the customization of adjuvant chemotherapy.

AB - Background: Molecular markers can help identify patients with early-stage non-small-cell lung cancer (NSCLC) with a high risk of relapse. Excision repair cross-complementing 1 (ERCC1), Xeroderma pigmentosum group G (XPG), and breast cancer 1 (BRCA1) are involved in DNA damage repair, whereas ribonucleotide reductase M1 (RRM1) is implicated in DNA synthesis. Expression levels of these molecules might therefore have a prognostic role in lung cancer. Patients and Methods: We examined ERCC1, RRM1, XPG, and BRCA1 mRNA levels by real-time quantitative polymerase chain reaction in 54 patients with stage IB-IIB resected NSCLC. A strong correlation was observed between the 4 genes. Results: For patients with low BRCA1, regardless of XPG mRNA expression levels, disease-free survival (DFS) was not reached. For patients with intermediate/high BRCA1 and high XPG, DFS was 50.7 months. However, for patients with intermediate/high BRCA1 and low/intermediate XPG, DFS decreased to 16.3 months (P = .002). Similar differences were observed in overall survival, with median survival not reached for patients with low BRCA1, regardless of XPG levels, or for patients with intermediate/high BRCA1 and high XPG. Conversely, for patients with intermediate/high BRCA1 levels and low/intermediate XPG levels, median sur vival dropped to 25.5 months (P = .007). Conclusion: BRCA1 and XPG were identified as independent prognostic factors for both median survival and DFS. High BRCA1 mRNA expression confers poor prognosis in early NSCLC, and the combination of high BRCA1 and low XPG expression still further increases the risk of shorter survival. These findings can help optimize the customization of adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=62549161737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549161737&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.007

DO - 10.3816/CLC.2009.n.007

M3 - Article

C2 - 19289372

AN - SCOPUS:62549161737

VL - 10

SP - 47

EP - 52

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -